CD56表达情况与多发性骨髓瘤患者预后关系-现代医学

CD56表达情况与多发性骨髓瘤患者预后关系

单位：1. 新乡医学院第一附属医院血液内科, 河南新乡 453100;
2. 新乡市淋巴瘤分子诊疗重点实验室, 河南新乡 453000;
3. 新乡市白血病分子诊疗重点实验室, 河南新乡 453000

分类号：R733.3

出版年·卷·期（页码）：2025·44·第六期（898-904）

摘要：

目的： 本研究旨在探讨CD56表达情况与多发性骨髓瘤(MM)患者预后关系。方法： 回顾性收集新乡医学院第一附属医院2018年8月至2023年12月收治的125例初诊MM患者的临床资料。将MM患者分为CD56阳性组和CD56阴性组，对比分析两组各项临床参数的差异、无进展生存期(PFS)和总生存期(OS)的差异，并进行Cox单因素及多因素分析。结果： CD56阳性组93例(74.4%)，CD56阴性组32例(25.6%)；MM患者的中位PFS和OS分别为32个月和未达到，平均PFS和OS分别为39.8个月和52.8个月；CD56阳性组的平均PFS和OS均长于CD56阴性组(平均PFS：42.5个月vs.30.8个月；平均OS：56.2个月vs.42.0个月，均P＜0.05)。Cox单因素分析显示，CD56阴性是MM患者PFS、OS短的影响因素(P＜0.05)。Cox多因素分析结果显示，CD56阴性是MM患者不良OS的独立危险因素(P＜0.05)。结论： CD56阴性与MM患者的不良预后密切相关。

Objective: To investigated the relationship between CD56 expression status and prognosis in patients with multiple myeloma(MM). Methods: Clinical data from 125 MM patients admitted to the First Affiliated Hospital of Xinxiang Medical University from August 2018 to December 2023 were retrospectively collected. Patients were divided into CD56-positive group and CD56-negative group. Differences in clinical parameters, progression-free survival(PFS), and overall survival(OS) between the two groups were compared. Univariate and multivariate Cox analysis were performed to identify prognostic factors.Results: Among 125 newly diagnosed MM patients, 93(74.4%) were CD56-positive and 32(25.6%) CD56-negative. The median PFS for all patients was 32 months, while median OS was not reached. The mean PFS and OS were 39.8 months and 52.8 months, respectively. The CD56-positive group showed significantly longer mean PFS and OS compared to the CD56-negative group(PFS: 42.5 vs. 30.8 months; OS: 56.2 vs. 42.0 months; both P<0.05). Univariate Cox analysis indicated CD56 negativity was associated with shorter PFS and OS(both P<0.05). Multivariate analysis confirmed CD56 negativity as an independent risk factor for poor OS(P<0.05). Conclusion: CD56 negativity is closely associated with adverse prognosis in MM patients.

参考文献：

[1] 刘灵娟,张一,高冲,等.血液系统疾病相关多原发癌的研究进展[J].现代医学,2023,51(3):416-420.
[2] COWAN A J,GREEN D J,KWOK M,et al.Diagnosis and management of multiple myeloma:a review[J].JAMA,2022,327(5):464-477.
[3] BRAYLAN R C.Impact of flow cytometry on the diagnosis and characterization of lymphomas,chronic lymphoproliferative disorders and plasma cell neoplasias[J].Cytometry A,2004,58(1):57-61.
[4] SKERGET M,SKOPEC B,ZADNIK V,et al.CD56 expression is an important prognostic factor in multiple myeloma even with bortezomib induction[J].Acta Haematol,2018,139(4):228-234.
[5] RAWSTRON A C,ORFAO A,BEKSAC M,et al.Report of the European Myeloma Network on multiparametric flow cytometry in multiple myeloma and related disorders[J].Haematologica,2008,93(3):431-438.
[6] SAHARA N,TAKESHITA A,SHIGENO K,et al.Clinicopathological and prognostic characteristics of CD56-negative multiple myeloma[J].Br J Haematol,2002,117(4):882-885.
[7] LI L,LI X,SHANG A,et al.Prognostic significance of CD56 antigen in newly diagnosed multiple myeloma:a real-world retrospective study[J].Medicine(Baltimore),2022,101(40):e30988.
[8] 王晓雪,张露露,王童,等.CD56表达情况在初诊多发性骨髓瘤患者预后中的价值及相关因素分析[J].中国实验血液学杂志,2023,31(3):777-782.
[9] MATHEW P,AHMANN G J,WITZIG T E,et al.Clinicopathological correlates of CD56 expression in multiple myeloma:a unique entity?[J].Br J Haematol,1995,90(2):459-461.
[10] KRAJ M,SOKOŁOWSKA U,KOPEĆ-SZLEZAK J,et al.Clinicopathological correlates of plasma cell CD56(NCAM) expression in multiple myeloma[J].Leuk Lymphoma,2008,49(2):298-305.
[11] HUNDEMER M,KLEIN U,HOSE D,et al.Lack of CD56 expression on myeloma cells is not a marker for poor prognosis in patients treated by high-dose chemotherapy and is associated with translocation t(11;14)[J].Bone Marrow Transplant,2007,40(11):1033-1037.
[12] CHANG H,SAMIEE S,YI Q L.Prognostic relevance of CD56 expression in multiple myeloma:a study including 107 cases treated with high-dose melphalan-based chemotherapy and autologous stem cell transplant[J].Leuk Lymphoma,2006,47(1):43-47.
[13] KOUMPIS E,TASSI I,MALEA T,et al.CD56 expression in multiple myeloma:correlation with poor prognostic markers but no effect on outcome[J].Pathol Res Pract,2021,225:153567.
[14] 中国医师协会血液科医师分会,中华医学会血液学分会.中国多发性骨髓瘤诊治指南(2022年修订)[J].中华内科杂志,2022,61(5):480-487.
[15] LEBEL E,NACHMIAS B,PICK M,et al.Understanding the bioactivity and prognostic implication of commonly used surface antigens in multiple myeloma[J].J Clin Med,2022,11(7):1809.
[16] VAN CAMP B,DURIE B G,SPIER C,et al.Plasma cells in multiple myeloma express a natural killer cell-associated antigen:CD56(NKH-1; Leu-19)[J].Blood,1990,76(2):377-382.
[17] COTTINI F,RODRIGUEZ J,HUGHES T,et al.Redefining CD56 as a biomarker and therapeutic target in multiple myeloma[J].Mol Cancer Res,2022,20(7):1083-1095.
[18] 邓银芬,袁红建,孙善芳.流式细胞术检测多发性骨髓瘤患者免疫表型的意义[J].临床医药文献电子杂志,2017,4(96):18945-18946.
[19] 苏显都,林榕,徐晓兰,等.47例多发性骨髓瘤细胞形态学及免疫表型特征分析[J].中国实验血液学杂志,2015,23(1):137-141.
[20] 王权钢,白波,马梁明,等.初诊多发性骨髓瘤患者CD56表达与以硼替佐米联合来那度胺为基础方案诱导治疗疗效的临床研究[J].临床血液学杂志,2022,35(11):821-825.

服务与反馈：

【文章下载】【发表评论】【查看评论】【加入收藏】

提示：您还未登录，请登录！点此登录